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background: We assessed relationship between late vascular inflammation after DES implantation and major adverse cardiac event (MACE) by 
C-reactive protein (CRP).
Methods: Paired CRP (baseline, and 8months after PCI as late phase) was available in 1176 patients who underwent PCI with DES (sirolimus; 500, 
paclitaxel; 319, everolimus;191, biolimus; 166). Elevated CRP was defined as over 0.2mg/dl. We investigated occurrence of MACE which comprises 
from all cause death, non-fatal myocardial infarction, and target lesion revascularization (TLR) among them.
results: Of all, elevated CRP at baseline was seen in 38.1 %, and it was decreased to 23.7% (including late-onset 9.3%) at late phase. By survival 
analysis, occurrence of MACE was powerfully related to late phase-CRP than baseline-CRP (shown in figure). Multivariate analysis revealed that 
elevated late phase-CRP (hazard ratio: HR; 4.31, 95% confidence interval: 95%CI; 2.98-6.24,P<0.0001) and CKD (eGFR<60ml/min; HR; 1.70, 
95%CI; 1.19-2.44, P=0.004) were independent predictor of occurrence of MACE. Prevalence of elevated late phase-CRP was different among stent 
types (sirolimus;28.0 %, paclitaxel; 24.8%, everolimus;18.3%, biolimus; 15.1%,P=0.002) .
conclusions: Elevated late phase-CRP may identify high risk subset of future MACE among patients who underwent DES implantation. Second 
generation DES with lower late inflammation might be better for long-term success.
